Stocktoria

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-7.27
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$263.5M-$391.0M-$336.2M$698.6M
2024$164.1M-$372.2M-$364.0M$710.4M
2023$1.2M-$444.0M-$384.1M$584.6M
2022-$395.9M-$313.2M$499.6M
2021-$342.3M-$265.5M$621.7M
2020-$259.6M-$251.9M$656.5M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Vogt Frederick GInterim CEO & General Counsel2026-06-05Option exercise15,625
Vogt Frederick GInterim CEO & General Counsel2026-06-05Tax withheld6,638$4.23
GRAF FINCKENSTEIN FRIEDRICHChief Medical Officer2026-06-05Option exercise7,813
GRAF FINCKENSTEIN FRIEDRICHChief Medical Officer2026-06-05Tax withheld3,976$4.23
Puri Raj K.Chief Regulatory Officer2026-06-05Option exercise9,766
Puri Raj K.Chief Regulatory Officer2026-06-05Tax withheld3,843$4.23
BILINSKY IGORChief Operating Officer2026-06-05Option exercise7,813
BILINSKY IGORChief Operating Officer2026-06-05Tax withheld3,976$4.23

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -7.27 (distress)

  • Working capital / assets 0.333
  • Retained earnings / assets -3.039
  • EBIT / assets -0.442
  • Equity / liabilities 3.255

Source: SEC EDGAR filings · CIK 0001425205 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.